

# OHIO Diabetes Data & Forecasts

State Total Population Forecasts	2015	2020	2025	2030
Entire Population	11,635,400	11,644,100	11,605,700	11,550,500
Prediabetes	3,114,300	3,219,300	3,304,800	3,293,400
Diagnosed diabetes	1,022,800	1,212,400	1,358,600	1,460,000
Undiagnosed diabetes	328,000	369,200	392,600	399,700
Total with diabetes (diagnosed and undiagnosed)	1,350,800	1,581,600	1,751,100	1,859,700
<b>Complications:</b>				
Visual impairment	167,700	193,000	209,900	219,000
Renal failure	2,440	2,790	3,020	3,130
Leg amputations	2,120	2,300	2,380	2,350
Annual deaths attributable to diabetes	11,020	12,470	13,260	13,500
Total annual cost (2015 dollars)	\$13.8 B	\$16.1 B	\$17.8 B	\$18.9 B
Annual medical costs	\$10.3 B	\$12.0 B	\$13.2 B	\$14.0 B
Annual nonmedical costs	\$3.5 B	\$4.1 B	\$4.6 B	\$4.9 B

State Senior Population Forecasts	2015	2020	2025	2030
Population 65 and older	1,766,200	1,978,500	2,206,700	2,357,000
Prediabetes	900,800	1,009,000	1,125,400	1,202,100
Diagnosed diabetes	333,800	373,900	417,100	445,500
Undiagnosed diabetes	123,600	138,500	154,500	165,000
Total with diabetes (diagnosed and undiagnosed)	457,500	512,400	571,500	610,500
<b>Complications:</b>				
Visual impairment	62,500	68,100	74,100	77,100
Renal failure	1,030	1,110	1,200	1,240
Leg amputations	770	800	820	820
Annual deaths attributable to diabetes	7,600	8,350	8,620	8,500
Total annual cost (2015 dollars)	\$5.8 B	\$6.5 B	\$7.3 B	\$7.8 B
Annual medical costs	\$5.5 B	\$6.1 B	\$6.8 B	\$7.3 B
Annual nonmedical costs	\$0.3 B	\$0.4 B	\$0.5 B	\$0.5 B

These forecasts are based on the latest available national diabetes data, including U.S Census Bureau population projections, the CDC National Diabetes Statistics Report, 2014, CDC diabetes morbidity trend reports, CDC's latest diabetes prevalence projections to 2050 and Dall, et al. "The Economic Burden of Elevated Blood Glucose Levels in 2012: Diagnosed and Undiagnosed Diabetes, Gestational Diabetes Mellitus, and Prediabetes," *Diabetes Care* 2014;37:3172-3179. These forecasts assume a steady, but conservative, reduction in the number of people with complications due to better awareness of the risks of diabetes, earlier screening and intervention, and more effective therapies.

For details and references on the Institute for Alternative Futures Diabetes 2030 Forecasting Model Methodology, visit [www.altfutures.org/diabetes2030](http://www.altfutures.org/diabetes2030).

Research funded by Novo Nordisk Inc.